Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose, including a diuretic.
Conditions
Brief summary
Change from baseline in ambulatory 24‑hour average SBP at Week 12.
Detailed description
Change from baseline in ambulatory night-time average SBP at Week 12., Change from baseline in ambulatory daytime average SBP at Week 12., Change from baseline in seated SBP at Week 12., Participants achieving ambulatory 24-hour average SBP of < 130 mmHg at Week 12., Change from baseline in ambulatory 24-hour average DBP at Week 12., Change from baseline in ambulatory night-time average DBP at Week 12., Change from baseline in ambulatory daytime average DBP at Week 12., Change from baseline on seated DBP at Week 12., Participants achieving a nocturnal SBP dipping of ≥ 10% at Week 12
Interventions
DRUGBaxdrostat
Sponsors
Astrazeneca AB
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in ambulatory 24‑hour average SBP at Week 12. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in ambulatory night-time average SBP at Week 12., Change from baseline in ambulatory daytime average SBP at Week 12., Change from baseline in seated SBP at Week 12., Participants achieving ambulatory 24-hour average SBP of < 130 mmHg at Week 12., Change from baseline in ambulatory 24-hour average DBP at Week 12., Change from baseline in ambulatory night-time average DBP at Week 12., Change from baseline in ambulatory daytime average DBP at Week 12., Change from baseline on seated DBP at Week 12., Participants achieving a nocturnal SBP dipping of ≥ 10% at Week 12 | — |
Countries
Belgium, Bulgaria, Czechia, Germany, Greece, Hungary, Poland, Slovakia, Spain
Outcome results
None listed